US-Danish Biotech firm Y-mabs, which is listed on US Stock Exchange Nasdaq, has submitted a new application for marketing authorization for a cancer treatment. This was revealed after the close of trading on Tuesday.
The application revolves around the drug omburtamab and its use in pediatric patients with central nervous system (CNS)/leptomeningeal metastasis from neuroblastoma, a type of cancer.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.